Pulmonary arterial hypertension

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Montani, David ^a,b,c   Günther, Sven ^a,b,c   Dorfmüller, Peter ^a,b,c   Perros, Frédéric ^a,b,c   Girerd, Barbara ^a,b,c   Garcia, Gilles ^a,b,c   Jaïs, Xavier ^a,b,c   Savale, Laurent ^a,b,c   Artaud Macari, Elise ^a,b,c   Price, Laura C ^d   Humbert, Marc ^a,b,c   Simonneau, Gérald ^a,b,c   Sitbon, Olivier ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; AMBRISENTAN; AMLODIPINE; ANTICOAGULANT AGENT; BENFLUOREX; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; DIGITALIS; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOGLIN; FENFLURAMINE; ILOPROST; IMATINIB; MACITENTAN; NIFEDIPINE; PLACEBO; PROSTACYCLIN; RIOCIGUAT; SELEXIPAG; SILDENAFIL; SMAD8 PROTEIN; TADALAFIL; TREPROSTINIL; VARDENAFIL;

ABSENCE OF SIDE EFFECTS; ANTICOAGULANT THERAPY; ARTERIAL GAS; ARTERY INTIMA; ARTERY LESION; AUTOIMMUNITY; CARDIOVASCULAR MAGNETIC RESONANCE; CELLULAR PARAMETERS; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTRACEPTION; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIURETIC THERAPY; DOPPLER ECHOCARDIOGRAPHY; DRUG HALF LIFE; DRUG MEGADOSE; DYSPEPSIA; ELECTROCARDIOGRAPHY; EXERCISE TEST; FAMILIAL DISEASE; FIBROSIS; FLUSHING; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HEART CATHETERIZATION; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTROPHY; HYPOTENSION; HYPOXIA; IDIOPATHIC DISEASE; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; JAW PAIN; LIMB PAIN; LUNG ANGIOGRAPHY; LUNG FUNCTION TEST; LUNG SCINTISCANNING; LUNG TRANSPLANTATION; LUNG VENTILATION; METABOLIC DISORDER; NAUSEA; NEW YORK HEART ASSOCIATION CLASS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POLYCYTHEMIA VERA; PORTOPULMONARY HYPERTENSION; PREGNANCY; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REHABILITATION CARE; REVIEW; RISK FACTOR; SCHISTOSOMIASIS; SEROLOGY; SIDE EFFECT; SYSTEMIC DISEASE; THORAX RADIOGRAPHY; THROMBOCYTHEMIA; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; VEIN INJURY; VOMITING; CLASSIFICATION; COMPLICATION; HEART DISEASE; HYPERTENSION, PULMONARY;

HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY;

EID: 84879816142     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-97     Document Type: Review

References (279)

1. Primary pulmonary hypertension. Rubin LJ, N Engl J Med 1997 336 2 111 7 (Pubitemid 27020889)
2. Updated clinical classification of pulmonary hypertension. Simonneau G, et al. J Am Coll Cardiol 2009 54 1 Suppl 43 54
3. Primary pulmonary hypertension: a pathological study of the lung vessels in 156 clinically diagnosed cases. Wagenvoort CA, Wagenvoort N, Circulation 1970 42 1163 84
4. Hatano S, Strasser T, Primary Pulmonary Hypertension. Report on a WHO meeting. October 15-17, 1973 Geneva: WHO 1975
5. Clinical classification of pulmonary hypertension. Fishman AP, Clin Chest Med 2001 22 3 385 91 vii (Pubitemid 32912074)
6. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Cogan JD, et al. Am J Respir Crit Care Med 2006 174 5 590 8 (Pubitemid 44330553)
7. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Aldred MA, et al. Hum Mutat 2006 27 2 212 3
8. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. Shintani M, et al. J Med Genet 2009 46 5 331 7
9. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Nasim MT, et al. Hum Mutat 2011 2011 2011
10. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Austin ED, et al. Circ Cardiovasc Genet 2012 5 3 336 43
11. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Machado RD, et al. Hum Mutat 2006 27 2 121 32 (Pubitemid 43238027)
12. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-ß family. Thomson JR, et al. J Med Genet 2000 37 741 5
13. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Chaouat A, et al. Thorax 2004 59 5 446 8 (Pubitemid 38624754)
14. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. Trembath RC, et al. N Engl J Med 2001 345 5 325 34 (Pubitemid 32703235)
15. Guidelines for the diagnosis and treatment of pulmonary hypertension. Galie N, et al. Eur Respir J 2009 34 6 1219 63
16. Clinical classification of pulmonary hypertension. Simonneau G, et al. J Am Coll Cardiol 2004 43 12 Suppl S 5S 12S (Pubitemid 38759712)
17. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Souza R, et al. Eur Respir J 2008 31 2 343 8
18. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Rich S, et al. Chest 2000 117 3 870 4 (Pubitemid 30152231)
19. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Walker AM, et al. Am Heart J 2006 152 3 521 6 (Pubitemid 44233427)
20. Benfluorex and unexplained valvular heart disease: a case-control study. Frachon I, et al. PLoS One 2010 5 4 10128
21. Pulmonary hypertension associated with benfluorex exposure. Savale L, et al. Eur Respir J 2012 40 5 1164 72
22. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chin KM, Channick RN, Rubin LJ, Chest 2006 130 6 1657 63 (Pubitemid 46033416)
23. Pulmonary arterial hypertension in patients treated by dasatinib. Montani D, et al. Circulation 2012 125 17 2128 37
24. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Hachulla E, et al. Arthritis Rheum 2005 52 12 3792 800 (Pubitemid 41798217)
25. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Mukerjee D, et al. Ann Rheum Dis 2003 62 11 1088 93 (Pubitemid 37323574)
26. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. Launay D, et al. J Rheumatol 2007 34 5 1005 11 (Pubitemid 46774846)
27. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. de Groote P, et al. Ann Rheum Dis 2008 67 1 31 6
28. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Meune C, et al. Arthritis Rheum 2008 58 6 1803 9 (Pubitemid 351847535)
29. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Kim KK, Factor SM, Hum Pathol 1987 18 12 1293 6 (Pubitemid 18018963)
30. HIV-Related pulmonary hypertension: analytic review of 131 cases. Mehta NJ, et al. Chest 2000 118 4 1133 41
31. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Opravil M, et al. Am J Respir Crit Care Med 1997 155 3 990 5 (Pubitemid 27133414)
32. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Sitbon O, et al. Am J Respir Crit Care Med 2008 177 1 108 13
33. Pulmonary vascular disorders in portal hypertension. Herve P, et al. Eur Respir J 1998 11 5 1153 66 (Pubitemid 28281039)
34. Pulmonary-Hepatic vascular Disorders (PHD). Rodriguez-Roisin R, et al. Eur Respir J 2004 24 5 861 880 (Pubitemid 39504442)
35. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Hadengue A, et al. Gastroenterology 1991 100 2 520 8
36. Portopulmonary hypertension: Results from a 10-year screening algorithm. Krowka MJ, et al. Hepatology 2006 44 6 1502 10 (Pubitemid 44953655)
37. Die angeborene defecte der kammersheidewand des herzen. Eisenmenger V, Z Klin Med 1897 132 1
38. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Wood P, Br Med J 1958 2 701 712
39. Eisenmenger syndrome. Factors relating to deterioration and death. Daliento L, et al. Eur Heart J 1998 19 12 1845 55 (Pubitemid 28556655)
40. Atrial Septal Defect with Pulmonary Hypertension. Besterman E, Br Heart J 1961 23 5 587 598
41. The natural history of ventricular septal defects in infancy. Hoffman JI, Rudolph AM, Am J Cardiol 1965 16 5 634 53
42. [Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo]. Lapa MS, et al. Rev Assoc Med Bras 2006 52 3 139 43 (Pubitemid 44105373)
43. The pathology of the arterial pulmonary vasculature in manson's schistosomiasis. Chaves E, Dis Chest 1966 50 1 72 7
44. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis-prospective study. de Cleva R, et al. Hepatogastroenterology 2003 50 54 2028 30 (Pubitemid 37467987)
45. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Lapa M, et al. Circulation 2009 119 11 1518 23
46. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Castro O, Hoque M, Brown BD, Blood 2003 101 4 1257 61 (Pubitemid 36182493)
47. Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. Gladwin MT, et al. N Engl J Med 2004 350 9 886 895 (Pubitemid 38252536)
48. Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Aessopos A, et al. Chest 1995 107 1 50 3
49. Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. Smedema JP, Louw VJ, Cardiovasc J Afr 2007 18 2 84 9
50. An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Jais X, et al. Hemoglobin 2003 27 3 139 47 (Pubitemid 36962047)
51. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. Stuard ID, Heusinkveld RS, Moss AJ, N Engl J Med 1972 287 17 869 70
52. A hemodynamic study of pulmonary hypertension in sickle cell disease. Parent F, et al. N Engl J Med 2011 365 1 44 53
53. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Montani D, et al. Medicine (Baltimore) 2008 87 4 220 33
54. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Lantuejoul S, et al. Am J Surg Pathol 2006 30 7 850 7 (Pubitemid 44264975)
55. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Resten A, et al. AJR Am J Roentgenol 2004 183 1 65 70 (Pubitemid 38789013)
56. Pulmonary veno-occlusive disease: a case series and new observations. Holcomb BW Jr, et al. Chest 2000 118 6 1671 9 (Pubitemid 32001794)
57. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. Dufour B, et al. AJR Am J Roentgenol 1998 171 5 1321 4 (Pubitemid 28489421)
58. Pulmonary veno-occlusive disease. Montani D, et al. Eur Respir J 2009 33 1 189 200
59. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Rabiller A, et al. Eur Respir J 2006 27 1 108 13 (Pubitemid 43092673)
60. Pulmonary hypertension associated with left-sided heart disease. Oudiz RJ, Clin Chest Med 2007 28 1 233 41 (Pubitemid 46350735)
61. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Abramson SV, et al. Ann Intern Med 1992 116 11 888 95 (Pubitemid 23034779)
62. Regression of extreme pulmonary hypertension after mitral valve surgery. Zener JC, et al. Am J Cardiol 1972 30 8 820 6
63. Effects of Mitral-Valve Replacement on the Pulmonary Vascular Dynamics of Patients with Pulmonary Hypertension. Braunwald E, et al. N Engl J Med 1965 273 509 14
64. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Delgado JF, et al. Eur J Heart Fail 2005 7 6 1011 6 (Pubitemid 41443595)
65. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Moraes DL, Colucci WS, Givertz MM, Circulation 2000 102 14 1718 23
66. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Fraser KL, et al. Chest 1999 115 5 1321 8 (Pubitemid 29230641)
67. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Cottin V, et al. Eur Respir J 2005 26 4 586 93 (Pubitemid 41448654)
68. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Weitzenblum E, et al. Thorax 1981 36 10 752 8 (Pubitemid 12249743)
69. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Thabut G, et al. Chest 2005 127 5 1531 6 (Pubitemid 46218776)
70. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Chaouat A, et al. Am J Respir Crit Care Med 2005 172 2 189 94 (Pubitemid 40981192)
71. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Tapson VF, Humbert M, Proc Am Thorac Soc 2006 3 7 564 7 (Pubitemid 44411620)
72. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. Pengo V, et al. N Engl J Med 2004 350 22 2257 64
73. Assessment of operability in chronic thromboembolic pulmonary hypertension. Kim NH, Proc Am Thorac Soc 2006 3 7 584 8 (Pubitemid 44411624)
74. Chronic thromboembolic pulmonary hypertension. Dartevelle P, et al. Eur Respir J 2004 23 4 637 48 (Pubitemid 38456010)
75. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Jamieson SW, et al. Ann Thorac Surg 2003 76 5 1457 62 discussion 1462-4
76. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Suntharalingam J, et al. Chest 2008 134 2 229 36
77. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Jais X, et al. Arthritis Rheum 2008 58 2 521 31 (Pubitemid 351294886)
78. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Rubin LJ, et al. Proc Am Thorac Soc 2006 3 7 601 7 (Pubitemid 44411627)
79. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Dingli D, et al. Chest 2001 120 3 801 8 (Pubitemid 32885453)
80. Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases. Guilpain P, et al. Respiration 2008 76 295 302
81. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Marvin KS, Spellberg RD, Chest 1993 103 2 642 4 (Pubitemid 23070789)
82. Pulmonary hypertension in polycythemia vera. Nand S, Orfei E, Am J Hematol 1994 47 3 242 4 (Pubitemid 24333458)
83. Pulmonary hypertension after splenectomy: a consequence of loss of the splenic filter or is there something more? Peacock AJ, Thorax 2005 60 12 983 4 (Pubitemid 41705463)
84. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Gluskowski J, et al. Respiration 1984 46 1 26 32 (Pubitemid 14054225)
85. Clinical predictors of pulmonary hypertension in sarcoidosis. Bourbonnais JM, Samavati L, Eur Respir J 2008 32 2 296 302
86. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Handa T, et al. Chest 2006 129 5 1246 52
87. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Nunes H, et al. Thorax 2006 61 1 68 74 (Pubitemid 43106981)
88. Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Dauriat G, et al. Transplantation 2006 81 5 746 50
89. Severe pulmonary hypertension in histiocytosis X. Fartoukh M, et al. Am J Respir Crit Care Med 2000 161 1 216 23 (Pubitemid 30055928)
90. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Harari S, et al. Chest 1997 111 4 1142 4
91. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Cottin V, et al. Eur Respir J 2012 40 3 630 40
92. Pulmonary hypertension in patients with neurofibromatosis type I. Montani D, et al. Medicine (Baltimore) 2011 90 3 201 11
93. Pulmonary hypertension in type I glycogen storage disease. Hamaoka K, et al. Pediatr Cardiol 1990 11 1 54 6 (Pubitemid 20097977)
94. [Pulmonary hypertension due to glycogen storage disease type II (Pompe's disease): a case report]. Inoue S, et al. J Cardiol 1989 19 1 323 32 (Pubitemid 19272034)
95. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Humbert M, et al. Eur Respir J 2002 20 1 59 65 (Pubitemid 34822922)
96. Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension. Pizzo CJ, Pediatrics 1980 65 2 341 3 (Pubitemid 10068603)
97. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Elstein D, et al. Lancet 1998 351 9115 1544 6 (Pubitemid 28230889)
98. The frequency and type of lung involvement in patients with Gaucher's disease. Lee R, Yousem S, Lab Invest 1998 58 54 A (Abstract)
99. Cytomegalovirus and autoimmune liver disease. Theise ND, Scheuer PJ, Grundy JE, J Clin Pathol 1989 42 12 1310 1 (Pubitemid 20035925)
100. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chu JW, et al. Chest 2002 122 5 1668 73 (Pubitemid 35366080)
101. Surgical treatment of pulmonary artery sarcoma. Mayer E, et al. J Thorac Cardiovasc Surg 2001 121 1 77 82 (Pubitemid 32105326)
102. Primary pulmonary artery sarcoma: a report of six cases. Anderson MB, et al. Ann Thorac Surg 1995 59 6 1487 90
103. Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma. Mussot S, et al. Eur J Cardiothorac Surg 2013 43 4 787 93
104. Pulmonary hypertension in patients with end-stage renal disease. Yigla M, et al. Chest 2003 123 5 1577 82 (Pubitemid 36549778)
105. Primary pulmonary hypertension. A national prospective study. Rich S, et al. Ann Intern Med 1987 107 2 216 23 (Pubitemid 17137857)
106. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. D'Alonzo GE, et al. Ann Intern Med 1991 115 5 343 9
107. Treatment of pulmonary arterial hypertension. Humbert M, Sitbon O, Simonneau G, N Engl J Med 2004 351 14 1425 36
108. Pulmonary arterial hypertension in France: results from a national registry. Humbert M, et al. Am J Respir Crit Care Med 2006 173 9 1023 30
109. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Humbert M, et al. Circulation 2010 122 2 156 63
110. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Benza RL, et al. Circulation 2010 122 2 164 72
111. Bone morphogenetic protein receptor 2 germline mutations in pulmonary arterial hypertension associated with fenfluramine derivatives. Humbert M, et al. Eur Respir J 2002 20 3 518 523
112. Genetic association of the serotonin transporter in pulmonary arterial hypertension. Machado RD, et al. Am J Respir Crit Care Med 2006 173 7 793 7
113. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor. Thomson J, et al. J Heart Lung Transplant 2001 20 2 149
114. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Sztrymf B, et al. Am J Respir Crit Care Med 2008 177 12 1377 83 (Pubitemid 351860916)
115. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Loyd J, et al. Am J Respir Crit Care Med 1995 152 93 97
116. Familial primary pulmonary hypertension: clinical patterns. Loyd JE, Primm RK, Newman JH, Am Rev Respir Dis 1984 129 1 194 7 (Pubitemid 14176528)
117. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Deng Z, et al. Am J Hum Genet 2000 67 737 744 (Pubitemid 30659603)
118. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Lane KB, et al. Nat Genet 2000 26 1 81 4
119. Genetics and genomics of pulmonary arterial hypertension. Machado RD, et al. J Am Coll Cardiol 2009 54 1 Suppl 32 42
120. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Girerd B, et al. Am J Respir Crit Care Med 2010 181 8 851 61
121. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. Rosenzweig EB, et al. J Heart Lung Transplant 2008 27 6 668 74
122. Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension. Aldred MA, et al. Am J Respir Crit Care Med 2007 176 8 819 24 (Pubitemid 47598484)
123. Update in pulmonary hypertension 2008. Humbert M, Am J Respir Crit Care Med 2009 in press
124. Clinical and molecular genetic features of pulmonary hypertension in hereditary hemorrhagic telangiectasia. Trembath R, et al. N Engl J Med 2001 345 325 334 (Pubitemid 32703235)
125. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Abdalla SA, et al. Eur Respir J 2004 23 3 373 7 (Pubitemid 38344371)
126. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. Harrison RE, et al. J Med Genet 2003 40 12 865 71 (Pubitemid 38117534)
127. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Harrison RE, et al. Circulation 2005 111 4 435 41 (Pubitemid 40204427)
128. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Fujiwara M, et al. Circ J 2008 72 1 127 33 (Pubitemid 351413340)
129. Clinical Features of Pulmonary Arterial Hypertension in Young People with an ALK1 Mutation and Hereditary Hemorrhagic Telangiectasia. Smoot LB, et al. Arch Dis Child 2009 94 7 506 11
130. Évaluation pronostique de biomarqueurs dans l'hypertension artérielle pulmonaire. Cracowski JL, et al. Rev Mal Respir 2004 21 6 Pt 1 1137 43 (Pubitemid 40260468)
131. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta1 and bone morphogenetic proteins. Morrell N, et al. Circulation 2001 104 790 795 (Pubitemid 32762677)
132. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Masri F, et al. Am J Physiol Lung Cell Mol Physiol 2007 293 3 548 54
133. Genes and pulmonary arterial hypertension. Sztrymf B, et al. Respiration 2007 74 2 123 32 (Pubitemid 46340871)
134. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Girerd B, et al. Respir Res 2010 11 73
135. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. West J, et al. BMC Med Genomics 2008 1 45
136. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Austin ED, et al. Eur Respir J 2009 34 5 1093 9
137. Treatment of pulmonary arterial hypertension with targeted therapies. O'Callaghan DS, et al. Nat Rev Cardiol 2011 8 9 526 38
138. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Stenmark KR, et al. Chest 2002 122 6 Suppl 326S 334S (Pubitemid 36043023)
139. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Davie NJ, et al. Am J Physiol Lung Cell Mol Physiol 2004 286 4 668 78
140. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Cool CD, et al. Am J Pathol 1999 155 2 411 9 (Pubitemid 29370391)
141. C-Kit Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. Montani D, et al. Am J Respir Crit Care Med 2011 184 1 116 23
142. Circulating fibrocytes and pulmonary arterial hypertension. Gambaryan N, et al. Eur Respir J 2012 39 1 210 2
143. Targeting of c-kit + haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Gambaryan N, et al. Eur Respir J 2011 37 6 1392 9
144. The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension. Kherbeck N, et al. Clin Rev Allergy Immunol 2013 44 1 31 8
145. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Balabanian K, et al. Am J Respir Crit Care Med 2002 165 10 1419 25 (Pubitemid 34522947)
146. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Itoh T, et al. Respirology 2006 11 2 158 63 (Pubitemid 43356895)
147. Autoimmunity and pulmonary hypertension: a perspective. Nicolls MR, et al. Eur Respir J 2005 26 6 1110 8 (Pubitemid 41829945)
148. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Perros F, et al. Eur Respir J 2007 29 3 462 8 (Pubitemid 46372091)
149. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Herve P, et al. Clin Chest Med 2001 22 3 451 8 (Pubitemid 32912078)
150. Increased plasma serotonin in primary pulmonary hypertension. Herve P, et al. Am J Med 1995 99 249 254
151. Leptin and regulatory T lymphocytes in idiopathic pulmonary arterial hypertension. Huertas A, et al. Eur Respir J 2012 40 4 895 904
152. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Perros F, et al. Am J Respir Crit Care Med 2012 185 3 311 21
153. Cellular and molecular pathobiology of pulmonary arterial hypertension. Humbert M, et al. J Am Coll Cardiol 2004 43 12 Suppl S 13S 24S (Pubitemid 38759713)
154. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. Christman BW, et al. N Engl J Med 1992 327 2 70 5
155. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Montani D, et al. Adv Ther 2009 26 9 813 25
156. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Petkov V, et al. J Clin Invest 2003 111 9 1339 46 (Pubitemid 36554704)
157. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Jeffery T, Morrell NW, Prog Cardiovasc Dis 2002 45 173 202 (Pubitemid 36139815)
158. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. Giaid A, et al. N Engl J Med 1993 328 24 1732 9 (Pubitemid 23170122)
159. Attenuated K + channel gene transcription in primary pulmonary hypertension. Yuan XJ, et al. Lancet 1998 351 9104 726 7
160. Dysfunctional voltage-gated K + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Yuan JX, et al. Circulation 1998 98 14 1400 6 (Pubitemid 28462800)
161. Anorexic Agents Aminorex, Fenfluramine, and Dexfenfluramine Inhibit Potassium Current in Rat Pulmonary Vascular Smooth Muscle and Cause Pulmonary Vasoconstriction. Weir EK, et al. Circulation 1996 94 9 2216 2220 (Pubitemid 26360516)
162. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. MacLean MR, et al. Br J Pharmacol 2000 131 2 161 8
163. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Marcos E, et al. Am J Respir Crit Care Med 2003 168 4 487 93 (Pubitemid 37046880)
164. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Keegan A, et al. Circ Res 2001 89 12 1231 9 (Pubitemid 34627883)
165. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Guilluy C, et al. Br J Pharmacol 2005 146 7 1010 8 (Pubitemid 41722174)
166. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Nagaoka T, et al. Am J Respir Crit Care Med 2005 171 5 494 9 (Pubitemid 40444250)
167. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Guilluy C, et al. Am J Respir Crit Care Med 2009 179 12 1151 8
168. HIF-1 and mechanisms of hypoxia sensing. Semenza GL, Curr Opin Cell Biol 2001 13 2 167 71 (Pubitemid 32209217)
169. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Semenza GL, Chest 2005 128 6 Suppl 592S 594S (Pubitemid 43054145)
170. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. Tuder RM, et al. J Pathol 2001 195 3 367 74
171. High altitude pulmonary hypertension: role of K + and Ca2+ channels. Remillard CV, Yuan JX, High Alt Med Biol 2005 6 2 133 46 (Pubitemid 41386663)
172. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Cool CD, et al. Hum Pathol 1997 28 4 434 42 (Pubitemid 27175084)
173. Pathologic assessment of vasculopathies in pulmonary hypertension. Pietra GG, et al. J Am Coll Cardiol 2004 43 12 Suppl S 25S 32S (Pubitemid 38759714)
174. Primary pulmonary hypertension: a histopathologic study of 80 cases. Bjornsson J, Edwards WD, Mayo Clin Proc 1985 60 1 16 25 (Pubitemid 15199621)
175. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Heath D, Edwards JE, Circulation 1958 18 4 Part 1 533 47
176. Inflammation in pulmonary arterial hypertension. Dorfmuller P, et al. Eur Respir J 2003 22 2 358 63 (Pubitemid 36987011)
177. Chemokine RANTES in severe pulmonary arterial hypertension. Dorfmuller P, et al. Am J Respir Crit Care Med 2002 165 4 534 9 (Pubitemid 34165478)
178. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Dorfmuller P, et al. Hum Pathol 2007 38 6 893 902 (Pubitemid 46735956)
179. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Overbeek MJ, et al. Eur Respir J 2009 34 2 371 9
180. Occult pulmonary haemorrhage in leukaemia. Golde DW, et al. Br Med J 1975 2 5964 166 8
181. Pulmonary capillary hemangiomatosis. Tron V, et al. Hum Pathol 1986 17 11 1144 50 (Pubitemid 17182897)
182. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Runo JR, et al. Am J Respir Crit Care Med 2003 167 6 889 94 (Pubitemid 36801778)
183. Diagnosis and differential assessment of pulmonary arterial hypertension. Barst RJ, et al. J Am Coll Cardiol 2004 43 12 Suppl S 40S 47S (Pubitemid 38759716)
184. Pulmonary veno-occlusive disease associated with severe reduction of single-breath carbon monoxide diffusing capacity. Elliott CG, et al. Respiration 1988 53 4 262 6
185. Exercise testing to estimate survival in pulmonary hypertension. Groepenhoff H, et al. Med Sci Sports Exerc 2008 40 10 1725 32
186. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Wensel R, et al. Circulation 2002 106 3 319 24 (Pubitemid 34778955)
187. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. McQuillan BM, et al. Circulation 2001 104 23 2797 802 (Pubitemid 33126653)
188. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. Tunariu N, et al. J Nucl Med 2007 48 5 680 4 (Pubitemid 47604965)
189. Diagnostic performance of state-of-the-art imaging techniques for morphological assessment of vascular abnormalities in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Ley S, et al. Eur Radiol 2012 22 3 607 16
190. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. Marcus JT, et al. J Am Coll Cardiol 2008 51 7 750 7 (Pubitemid 351221219)
191. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Haddad F, et al. Circulation 2008 117 11 1436 48 (Pubitemid 351501496)
192. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Galie N, et al. Eur Heart J 2009 30 20 2493 537
193. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. van Wolferen SA, et al. Eur Heart J 2007 28 10 1250 7 (Pubitemid 47343830)
194. Hepatopulmonary syndrome and portopulmonary hypertension. Naeije R, Swiss Med Wkly 2003 133 11-12 163 9 (Pubitemid 36628590)
195. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. Hoeper MM, et al. J Am Coll Cardiol 2006 48 12 2546 52 (Pubitemid 44881214)
196. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Benza RL, et al. Chest 2012 141 2 354 62
197. Primary pulmonary hypertension: Current therapy. Sitbon O, Humbert M, Simonneau G, Prog Cardiovasc Dis 2002 45 2 115 28 (Pubitemid 35253678)
198. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Bonnin M, et al. Anesthesiology 2005 102 6 1133 7 discussion 5A-6A (Pubitemid 40745831)
199. Non-cardiothoracic non-obstetric surgery in mild-moderate pulmonary hypertension: Perioperative management of 28 consecutive individual cases. Price LC, et al. Eur Respir J 2010 35 6 1294 302
200. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Provencher S, et al. Eur Respir J 2006 27 1 114 20 (Pubitemid 43092674)
201. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. Sitbon O, et al. J Am Coll Cardiol 2002 40 4 780 8 (Pubitemid 34925627)
202. Primary pulmonary hypertension: natural history and the importance of thrombosis. Fuster V, et al. Circulation 1984 70 4 580 7 (Pubitemid 14020655)
203. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. Rich S, Kaufmann E, Levy PS, N Engl J Med 1992 327 2 76 81
204. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Rich S, et al. Chest 1998 114 3 787 92 (Pubitemid 28433741)
205. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Sitbon O, et al. Circulation 2005 111 23 3105 11 (Pubitemid 40847788)
206. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Moncada S, et al. Nature 1976 263 5579 663 5
207. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Rubin LJ, et al. Ann Intern Med 1990 112 7 485 91 (Pubitemid 20100285)
208. Treatment of pulmonary arterial hypertension with targeted therapies. O'Callaghan DS, et al. Nat Rev Cardiol 2011 8 9 526 38
209. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Higenbottam T, et al. Lancet 1984 1 8385 1046 7 (Pubitemid 14148935)
210. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Robbins IM, et al. Chest 1998 114 5 1269 75 (Pubitemid 28527397)
211. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. Barst RJ, et al. N Engl J Med 1996 334 5 296 302
212. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Badesch DB, et al. Ann Intern Med 2000 132 6 425 34 (Pubitemid 30149039)
213. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Barst RJ, et al. Ann Intern Med 1994 121 6 409 15
214. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. McLaughlin VV, Shillington A, Rich S, Circulation 2002 106 12 1477 82
215. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Rosenzweig EB, Kerstein D, Barst RJ, Circulation 1999 99 14 1858 65 (Pubitemid 29181415)
216. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Nunes H, et al. Am J Respir Crit Care Med 2003 167 10 1433 9 (Pubitemid 36609730)
217. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. Cabrol S, et al. J Heart Lung Transplant 2007 26 4 357 62 (Pubitemid 46522504)
218. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. McLaughlin VV, et al. N Engl J Med 1998 338 5 273 7 (Pubitemid 28065252)
219. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. Shapiro SM, et al. J Am Coll Cardiol 1997 30 2 343 9 (Pubitemid 27339311)
220. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. Laliberte K, et al. J Cardiovasc Pharmacol 2004 44 2 209 14 (Pubitemid 38982164)
221. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Simonneau G, et al. Am J Respir Crit Care Med 2002 165 6 800 4 (Pubitemid 34229650)
222. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV, et al. J Am Coll Cardiol 2010 55 18 1915 22
223. Inhaled iloprost for severe pulmonary hypertension. Olschewski H, et al. N Engl J Med 2002 347 5 322 9 (Pubitemid 34815354)
224. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. Hoeper MM, et al. N Engl J Med 2000 342 25 1866 70 (Pubitemid 30419050)
225. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Channick RN, et al. Lancet 2001 358 9288 1119 23 (Pubitemid 32971843)
226. Bosentan therapy for pulmonary arterial hypertension. Rubin LJ, et al. N Engl J Med 2002 346 12 896 903 (Pubitemid 34984638)
227. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Humbert M, et al. Eur Respir J 2004 24 3 353 9 (Pubitemid 39232254)
228. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Galie N, et al. Lancet 2008 371 9630 2093 100 (Pubitemid 351902178)
229. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Sitbon O, et al. Chest 2003 124 1 247 54 (Pubitemid 36851359)
230. Survival with first-line bosentan in patients with primary pulmonary hypertension. McLaughlin VV, et al. Eur Respir J 2005 25 2 244 9 (Pubitemid 40246523)
231. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Sitbon O, et al. Thorax 2005 60 12 1025 30 (Pubitemid 41705471)
232. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Galie N, et al. Circulation 2008 117 23 3010 9
233. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Klinger JR, et al. Am J Cardiol 2011 108 2 302 7
234. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Ghofrani HA, et al. Lancet 2002 360 9337 895 900 (Pubitemid 35283832)
235. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Schermuly RT, et al. Am J Respir Crit Care Med 2004 169 1 39 45 (Pubitemid 38233887)
236. Sildenafil citrate therapy for pulmonary arterial hypertension. Galie N, et al. N Engl J Med 2005 353 20 2148 57 (Pubitemid 41653106)
237. Tadalafil therapy for pulmonary arterial hypertension. Galie N, et al. Circulation 2009 119 22 2894 903
238. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Barst RJ, et al. J Heart Lung Transplant 2011 30 6 632 43
239. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Simonneau G, et al. Ann Intern Med 2008 149 8 521 30
240. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. McLaughlin VV, et al. Am J Respir Crit Care Med 2006 174 11 1257 63 (Pubitemid 44924827)
241. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Hoeper MM, et al. Eur Respir J 2003 22 2 330 4 (Pubitemid 36987006)
242. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Ghofrani HA, et al. J Am Coll Cardiol 2003 42 1 158 64 (Pubitemid 36760778)
243. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Gomberg-Maitland M, et al. Am J Cardiol 2005 96 9 1334 6 (Pubitemid 41505420)
244. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Hoeper MM, et al. Eur Respir J 2004 24 6 1007 10 (Pubitemid 39642293)
245. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Mathai SC, et al. Eur Respir J 2007 29 3 469 75 (Pubitemid 46372092)
246. Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial. Rubin L, et al. Chest 2012 142 1026A 1026A 10.1378/chest.1456207
247. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. Iglarz M, et al. J Pharmacol Exp Ther 2008 327 3 736 45
248. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Sidharta PN, et al. Eur J Clin Pharmacol 2011 67 10 977 84
249. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Jing ZC, et al. Am J Respir Crit Care Med 2011 183 12 1723 9
250. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Ghofrani HA, Grimminger F, Eur Respir Rev 2009 18 111 35 41
251. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Grimminger F, et al. Eur Respir J 2009 33 4 785 92
252. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Ghofrani HA, et al. Eur Respir J 2010 36 4 792 9
253. Riociguat for the treatment of pulmonary hypertension. Schermuly RT, et al. Expert Opin Investig Drugs 2011 20 4 567 76
254. Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. Ghio S, et al. Eur J Heart Fail 2012 14 8 946 53
255. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Hoeper MM, et al. Eur Respir J 2013 41 4 853 60
256. Riociguat for the Treatment of Pulmonary Arterial Hypertension. Ghofrani H, et al. N Engl J Med 2013 369 4 330 40
257. Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists. Asaki T, et al. Bioorg Med Chem 2007 15 21 6692 704 (Pubitemid 47385245)
258. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy] -N-(methylsulfonyl)acetam ide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. Kuwano K, et al. J Pharmacol Exp Ther 2007 322 3 1181 8 (Pubitemid 47295780)
259. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetam ide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino] butoxy}acetic acid (MRE-269), on rat pulmonary artery. Kuwano K, et al. J Pharmacol Exp Ther 2008 326 3 691 9
260. Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery. Morrison K, et al. J Pharmacol Exp Ther 2012 343 3 547 55
261. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Simonneau G, et al. Eur Respir J 2012 40 4 874 80
262. NIH, ClinicalTrials.gov. ACT-BR;293987 in pulmonary arterial hypertension [online] 2011
263. PDGF signaling in pulmonary arterial hypertension. Barst RJ, J Clin Invest 2005 115 10 2691 4 (Pubitemid 41434394)
264. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Perros F, et al. Am J Respir Crit Care Med 2008 178 1 81 8 (Pubitemid 351919196)
265. Mediators, cytokines, and growth factors in liver-lung interactions. Panos RJ, Baker SK, Clin Chest Med 1996 17 1 151 69
266. Reversal of experimental pulmonary hypertension by PDGF inhibition. Schermuly RT, et al. J Clin Invest 2005 115 10 2811 21 (Pubitemid 41434408)
267. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Ghofrani H, et al. Am J Respir Crit Care Med 2010 182 9 1171 7
268. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Hoeper MM, et al. Circulation 2013 127 10 1128 38
269. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Kerkela R, et al. Nat Med 2006 12 8 908 16 (Pubitemid 44175142)
270. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. McLaughlin VV, et al. Chest 2004 126 1 Suppl 78S 92S (Pubitemid 38932344)
271. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. Sandoval J, et al. J Am Coll Cardiol 1998 32 2 297 304 (Pubitemid 28396475)
272. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Rothman A, et al. Am J Cardiol 1999 84 6 682 6 (Pubitemid 29417961)
273. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Kerstein D, et al. Circulation 1995 91 7 2028 35
274. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Kurzyna M, et al. Chest 2007 131 4 977 83 (Pubitemid 46608695)
275. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. Hosenpud JD, et al. J Heart Lung Transplant 2001 20 8 805 15 (Pubitemid 32737517)
276. Single lung transplantation for primary pulmonary hypertension. Levine SM, et al. Chest 1990 98 5 1107 15 (Pubitemid 20381271)
277. Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. Pielsticker EJ, Martinez FJ, Rubenfire M, J Heart Lung Transplant 2001 20 12 1297 304 (Pubitemid 34017315)
278. Lung transplantation for pulmonary vascular disease. Mendeloff EN, et al. Ann Thorac Surg 2002 73 1 209 17 discussion 217-9
279. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. Reitz BA, et al. N Engl J Med 1982 306 10 557 64